Hosted on MSN2h
Oppenheimer Upgrades BioMarin Pharmaceutical (BMRN)
Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from ...
VI Consortium17h
Oppenheimer Beach Rehabilitation Underway with $1 Million EDA Grant; Bolques Proposes Name Change
Efforts are ongoing to rehabilitate the Oppenheimer Beach Facility on the island of St. John thanks to a $1 million grant ...
Oppenheimer upgrades BioMarin with stage set for increasing interest
Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...
Oppenheimer Reiterates Outperform Rating on NVIDIA, Citing AI Accelerator Demand
As NVIDIA increases the output of its next-generation Blackwell architecture, its AI hardwareespecially its H200 GPUsis ...
Oppenheimer's Rupesh Parikh on Walmart's Q4 results: There's really no blemish in this report
Rupesh Parikh, Oppenheimer managing director and senior analyst, joins 'Squawk Box' to break down Walmart's quarterly ...
Oppenheimer Bangs the Drum on Nvidia Stock Ahead of Earnings
Nvidia (NASDAQ:NVDA) is ready to turn the page on the DeepSeek drama and shift focus to its next big catalyst. The AI chip giant is set to ...
Jewish Telegraphic Agency6d
The Jewish story behind ‘Oppenheimer,’ explained
(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...
Oppenheimer Cuts Toll Brothers (NYSE:TOL) Price Target to $165.00
Toll Brothers (NYSE:TOL – Free Report) had its price objective cut by Oppenheimer from $189.00 to $165.00 in a research note ...
Netflix CCO claims that Christopher Nolan's Oppenheimer would have had same cultural impact if it was a Netflix exclusive
When Barbie and Oppenheimer graced our theatres, audiences were either skipping out of screens to the tune of "I'm Just Ken" ...
Oppenheimer维持Vaxart股票"跑赢大市"评级，关注BARDA停工令影响
周一，Oppenheimer重申对Vaxart Inc.（NASDAQ:VXRT）的"跑赢大市"评级，维持目标价USD 4.00不变，相较目前股价USD 0.51存在显著上涨空间。这家市值USD 1.15亿的生物科技公司近期因收到ATI/BARDA的停工令，导致其口服新冠疫苗Phase 2b研究暂停。该意外停工令于上周五收到，Vaxart管理层正积极寻求更多细节。
What Analysts Think of Nvidia Stock Ahead of Earnings
Nvidia is set to report fourth-quarter results after the market closes Wednesday, with analysts widely bullish on the AI chipmaker's stock.
Oppenheimer上调BioMarin评级至"优于大市"，目标价98美元
周一，Oppenheimer分析师上调了BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )的股票评级，从"持平"上调至"优于大市"，并设定目标价为$98.00。此次上调是基于BioMarin在2024年第四季度的强劲表现，公司总收入达到$747 million，超过市场预期的$712 ...